Biomaterials Research (생체재료학회지)

Korean Society for Biomaterials (한국생체재료학회)
권호 표지

Histopathological Analysis of Drug Eluting Stents in Porcine Coronary Restenosis Model

  • Lim, Kyung Seob (The Heart Research Center of Chonnam National University Hospital Designated by Korea Ministry of Health and Welfare) ;
  • Bae, In-Ho (The Heart Research Center of Chonnam National University Hospital Designated by Korea Ministry of Health and Welfare) ;
  • Park, Dae Sung (The Heart Research Center of Chonnam National University Hospital Designated by Korea Ministry of Health and Welfare) ;
  • Kim, Jong Min (The Heart Research Center of Chonnam National University Hospital Designated by Korea Ministry of Health and Welfare) ;
  • Jeong, Myung Ho (The Heart Research Center of Chonnam National University Hospital Designated by Korea Ministry of Health and Welfare)
  • Published : 2013.06.01
⟨ Previous Next ⟩

Abstract

The aim of this study was to compare the two types of drug-eluting stents with histological analysis in porcine coronary restenosis model. Pigs were randomized into two groups in which the coronary arteries (12 pigs, 12 coronaries in each group) had either biolimus-eluting stent with biodegradable polymer (BPS) or sirolimus-eluting stent with durable polymer (DPS). Radiological analysis was performed pre-stent and post-stent implantation and histopathologic analysis was assessed at 28 days after stenting. Angiographic finding showed that the coronary artery was more narrowed by neointima proliferation in BPS compared to DPS. In histopathological analysis, the internal elastic lamina (IEL), lumen area, neointima area, percent area stenosis, and fibrin score were significantly different between the two groups ($5.1{\pm}0.79mm^2$, $2.8{\pm}0.85mm^2$, $2.3{\pm}0.75 mm^2$, $45.9{\pm}13.43%$, $0.4{\pm}0.79$ in BPS group vs. $4.2{\pm}0.93mm^2$, $3.0{\pm}0.90mm^2$, $1.2{\pm}0.67 mm^2$, $28.1{\pm}14.81%$, $2.0{\pm}0.93$ in DPS group, respectively). However, there was no significant difference in injury and inflammation score ($1.3{\pm}0.40$, $1.0{\pm}0.31$ in BPS group vs. $1.3{\pm}0.32$, $1.1{\pm}0.15$ in DPS group, respectively). Our study demonstrated that BPS was not effective to reduce neointima hyperplasia at 1 month after implantation of stents in porcine coronary artery. However, fibrin score of BPS which means delayed arterial healing is very lower than that of DPS.

Keywords

References

  1. M. Sabate, P. Jimenez-Quevedo, D. J. Angiolillo, et. al., "Randomized comparison of sirolimus-eluting stent versus standard stent for percutaneous coronary revascularization in diabetic patients: the diabetes and sirolimus-eluting stent (DIABETES) trial," Circulation, 112, 2175-2183 (2005). https://doi.org/10.1161/CIRCULATIONAHA.105.562421
  2. M. C. Morice, P. W. Serruys, J. E. Sousa, et. al., "A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization," N. Engl. J. Med., 346, 1773-1780 (2002). https://doi.org/10.1056/NEJMoa012843
  3. J. B. Hermiller, A. Raizner, L. Cannon, et al., "Outcomes with the polymer-based paclitaxel-eluting TAXUS stent in patients with diabetes mellitus: the TAXUS-IV trial," J. Am. Coll. Cardiol., 45, 1172-1179 (2005). https://doi.org/10.1016/j.jacc.2004.10.075
  4. A. Gershlick, D. E. Kandzari, M. B. Leon, et al., "Zotarolimuseluting stents in patients with native coronary artery disease: clinical and angiographic outcomes in 1,317 patients," Am. J. Cardiol., 100, 45M-55M (2007).
  5. G. W. Stone, A. Rizvi, K. Sudhir, et al., "Randomized comparison of everolimus- and paclitaxel-eluting stents. 2-year follow-up from the SPIRIT (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) IV trial," J. Am. Coll. Cardiol., 58, 19-25 (2011). https://doi.org/10.1016/j.jacc.2011.02.022
  6. P. C. Smits, E. Kedhi, K. J. Royaards, et al., "2-year follow-up of a randomized controlled trial of everolimus- and paclitaxel-eluting stents for coronary revascularization in daily practice. COMPARE (Comparison of the everolimus eluting XIENCE-V stent with the paclitaxel eluting TAXUS LIBERTE stent in all-comers: a randomized open label trial)," J. Am. Coll. Cardiol., 58, 11-8 (2011). https://doi.org/10.1016/j.jacc.2011.02.023
  7. C. Stettler, S. Wandel, S. Allemann, et al., "Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis," Lancet, 370, 937-948(2007). https://doi.org/10.1016/S0140-6736(07)61444-5
  8. G. W. Stone, J. W. Moses, S. G. Ellis, et al., "Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents," N. Engl. J. Med., 356, 998-1008 (2007). https://doi.org/10.1056/NEJMoa067193
  9. P. K. Kuchulakanti, W. W. Chu, R. Torguson, et al., "Correlates and long-term outcomes of angiographically proven stent thrombosis with sirolimus- and paclitaxel-eluting stents," Circulation, 113, 1108-1113 (2006). https://doi.org/10.1161/CIRCULATIONAHA.105.600155
  10. G. G. Stefanini, B. Kalesan, P. W. Serruys, et al., "Long-term clinical outcomes of biodegradable polymer biolimus-eluting stents versus durable polymer sirolimus-eluting stents in patients with coronary artery disease (LEADERS): 4 year follow-up of a randomised non-inferiority trial," Lancet, 378, 1940-1948 (2011). https://doi.org/10.1016/S0140-6736(11)61672-3
  11. E. Kedhi, K. S. Joesoef, E. McFadden, et al., "Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial," Lancet, 375, 201-209 (2010). https://doi.org/10.1016/S0140-6736(09)62127-9
  12. G. W. Stone, M. Midei, W. Newman, et al., "Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: twoyear clinical follow-up from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions (SPIRIT) III trial," Circulation, 119, 680-686 (2009). https://doi.org/10.1161/CIRCULATIONAHA.108.803528
  13. R. Mehran, G. Dangas, A. S. Abizaid, et al., "Angiographic patterns of in-stent restenosis: classification and implications for long-term outcome," Circulation, 100, 1872-1878 (1999). https://doi.org/10.1161/01.CIR.100.18.1872
  14. R. S. Schwartz, K. C. Huber, J. G. Murphy, et al., "Restenosis and the proportional neointimal response to coronary artery injury: results in a porcine model," J. Am. Coll. Cardiol., 19, 267-274 (1992). https://doi.org/10.1016/0735-1097(92)90476-4
  15. R. S. Schwartz, E. Edelman, R. Virmani, et al., "Drug-eluting stents in preclinical studies: updated consensus recommendations for preclinical evaluation," Circ. Cardiovasc. Interv., 1, 143-153 (2008). https://doi.org/10.1161/CIRCINTERVENTIONS.108.789974
  16. A. Schomig, F. J. Neumann, A. Kastrati, et al., "A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents," N. Engl. J. Med., 334, 1084-1089 (1996). https://doi.org/10.1056/NEJM199604253341702
  17. A. Schomig, F. J. Neumann, H. Walter, et al., "Coronary stent placement in patients with acute myocardial infarction: comparison of clinical and angiographic outcome after randomization to antiplatelet or anticoagulant therapy," J. Am. Coll. Cardiol., 29, 28-34 (1997). https://doi.org/10.1016/S0735-1097(96)00450-0
  18. A. V. Finn, M. Joner, G. Nakazawa, et al., "Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization," Circulation, 115, 2435-2441 (2007). https://doi.org/10.1161/CIRCULATIONAHA.107.693739
  19. A. V. Finn, G. Nakazawa, M. Joner, et al., "Vascular responses to drug eluting stents: importance of delayed healing," Arterioscler. Thromb. Vasc. Biol., 27, 1500-1510 (2007). https://doi.org/10.1161/ATVBAHA.107.144220
  20. E. Grube, and L. Buellesfeld, "BioMatrix Biolimus A9-eluting coronary stent: a next-generation drug-eluting stent for coronary artery disease," Expert. Rev. Med. Devices., 3, 731-741 (2006). https://doi.org/10.1586/17434440.3.6.731
  21. S. Garg, G. Sarno, P. W. Serruys, et al., "The twelve-month outcomes of a biolimus eluting stent with a biodegradable polymer compared with a sirolimus eluting stent with a durable polymer," EuroIntervention, 6, 233-239 (2010). https://doi.org/10.4244/EIJV6I2A37
  22. S. Windecker, P. W. Serruys, S. Wandel, et al., "Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised non-inferiority trial," Lancet, 372, 1163-1173 (2008). https://doi.org/10.1016/S0140-6736(08)61244-1
  23. V. Klauss, P. W. Serruys, T. Pilgrim, et al., "2-year clinical followup from the randomized comparison of biolimus-eluting stents with biodegradable polymer and sirolimus-eluting stents with durable polymer in routine clinical practice," JACC. Cardiovasc. Interv. 4, 887-895 (2011). https://doi.org/10.1016/j.jcin.2011.03.017
  24. J. J. Wykrzykowska, L. Raber, T. de Vries, et al., "Biolimus-eluting biodegradable polymer versus sirolimus-eluting permanent polymer stent performance in long lesions: results from the LEADERS multicentre trial substudy," EuroIntervention, 5, 310-317 (2009). https://doi.org/10.4244/V5I3A49
  25. G. G. Stefanini, R. A. Byrne, P. W. Serruys, et al., "Biodegradable polymer drug-eluting stents reduce the risk of stent thrombosis at 4 years in patients undergoing percutaneous coronary intervention: a pooled analysis of individual patient data from the ISARTEST 3, ISAR-TEST 4, and LEADERS randomized trials," Eur. Heart J. 33, 1214-1222 (2012). https://doi.org/10.1093/eurheartj/ehs086